Implications of Failure to Routinely Diagnose Resistance to Second-Line Drugs in Patients With Rifampicin-Resistant Tuberculosis on Xpert MTB/RIF: A Multisite Observational Study

BACKGROUND. Xpert MTB/RIF (Xpert) detects rifampicin-resistant tuberculosis (RR-tuberculosis), enabling physicians to rapidly initiate a World Health Organization–recommended 5-drug regimen while awaiting second-line drug-susceptibility test (DST) results. We quantified the second-line DST results t...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Clin Infect Dis
Glavni autori: Jacobson, Karen R., Barnard, Marinus, Kleinman, Mary B., Streicher, Elizabeth M., Ragan, Elizabeth J., White, Laura F., Shapira, Ofer, Dolby, Tania, Simpson, John, Scott, Lesley, Stevens, Wendy, van Helden, Paul D., Van Rie, Annelies, Warren, Robin M.
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2017
Teme:
Major Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5434334/
https://ncbi.nlm.nih.gov/pubmed/28199520
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/cix128
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items